scholarly journals HMGB1, the Next Predictor of Transcatheter Arterial Chemoembolization for Liver Metastasis of Colorectal Cancer?

2020 ◽  
Vol 10 ◽  
Author(s):  
Yuan-dong Sun ◽  
Hao Zhang ◽  
Ye-qiang Chen ◽  
Chun-xue Wu ◽  
Jian-bo Zhang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Liver Injury ◽  
Ischemia Reperfusion Injury ◽  
Ischemia Reperfusion ◽  
Over Expression ◽  
Hmgb1 Expression ◽  
Prognostic Feature ◽  
One Year ◽  
The One

HMGB1 is an important mediator of inflammation during ischemia–reperfusion injury on organs. The serum expression of HMGB1 was increased significantly on the 1st day after TACE and decreased significantly which was lower on the 30th day after TACE. Tumor markers of post-DEB-TACE decreased significantly. The correlational analysis showed that patients with low HMGB1 expression had lower risks of fever and liver injury compared those with the higher expression, while the ORR is relatively worse. Patients with lower expression of HMGB1 had longer PFS, better efficacy, and higher quality of life. With the high post-expression, the low expression had lower incidence of fever and liver injury too. There was no statistical difference in the one-year survival among the different groups. The quality of life of all patients was improved significantly. The over-expression of HMGB1 in LMCRC is an adverse prognostic feature and a positive predictor of response to TACE.

scholarly journals Impact of Endovascular Treatment on Clinical Status and Health-Related Quality of Life

2008 ◽  
Vol 97 (1) ◽  
pp. 50-55 ◽  
Author(s):  
J. Virkkunen ◽  
M. Venermo ◽  
J. Saarinen ◽  
L. Keski-Nisula ◽  
P. Apuli ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Status ◽  
Critical Limb Ischaemia ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
One Year ◽  
The One

Background and Aims: Investigating the impact of percutaneous transluminal angioplasty (PTA) on clinical status and health related quality of life in patients with claudication and critical limb ischaemia (CLI). Material and Methods: 61 patients and 64 limbs underwent a primary PTA (30 claudication and 34 CLI cases). Clinical status was graded according to Ahn and Rutherford and ankle/brachial index (ABI). Quality of life was assessed using the Nottingham Health Profile (NHP) preoperatively, one month and one year after the procedure. Triplex scan evaluation of the treated arterial segment was carried out postoperatively and one year after the procedure. Results: Claudication: 24/27 patients underwent one-year follow up, after which 20/24 had no claudication. In triplex evaluation 17 (63.0%) treated segments were open with 0–50% restenosis, 9 (33.3%) with 51–99% restenosis and one (3.7%) was occluded. CLI: 13/34 (38.2%) patients underwent one-year follow-up after which eight patients (61.5%) were asymptomatic and five (38.1%) had claudication. In triplex evaluation there was 0–50% restenosis in 6 (46.2%) segments treated with PTA and 51–99% restenosis in 7 (53.8%) segments. 21 (61.8%) patients did not conclude the one year follow up: 7 had died, 5 had undergone bypass surgery and 6 an amputation and 3 did not attend the follow-up up for unknown reasons. Quality of life: For CLI patients, improvement was observed in the domain of pain, which continued throughout the follow-up period. Among the claudicants, the domain of physical mobility was improved at one month's follow-up, but this effect disappeared during the following year and could not be seen at one the one- year follow-up. Conclusions: Technical success and one-year results in claudication are good, and the rate of complications is low. However, although PTA resulted in an immediate improvement in the quality of life, this effect was not seen in the long term. In critical limb ischemia there was a group of patients in whom PTA led to a significant benefit in terms of limb salvage and quality of life.

scholarly journals O42 SURGICAL REPAIR OF DIASTASIS RECTI ABDOMINIS (DRA) PROVIDES LONG-TERM IMPROVEMENT OF ABDOMINAL CORE FUNCTION AND QUALITY OF LIFE: A THREE-YEAR FOLLOW-UP

2021 ◽  
Vol 108 (Supplement_8) ◽  
Author(s):  
Anders Olsson ◽  
Olivia Kiwanuka ◽  
Sofia Wilhelmsson ◽  
Gabriel Sandblom ◽  
Otto Stackelberg
Keyword(s):  
Quality Of Life ◽  
Surgical Repair ◽  
Post Partum ◽  
Diastasis Recti ◽  
Sf 36 ◽  
Core Function ◽  
One Year ◽  
The One

Abstract Aim Diastasis Recti Abdominis (DRA) is a condition affecting many post-partum women. The aim of this study was to evaluate long-term results of surgical repair of DRA in a cohort of post-partum women. Material and Methods Sixty post-partum women with DRA and training-resistant core dysfunctions were included. Surgical repair was performed with suture plication of the linea alba. Abdominal core function was evaluated with the Abdominal Trunk Function Protocol (ATFP) including a self-report questionnaire and seven functional tests. Urinary incontinence and Quality of Life was evaluated with the Urogenital Distress Inventory (UDI-6), the Incontinence Impact Questionnaire (IIQ-7) and the SF-36 questionnaire. Follow-up was performed at one year and three years’ post-operatively. Results Response rate at the three-year follow-up was 86.7 % for the DRI questionnaire; and 71.7% for ATFP, the UDI-6, IIQ-7, and SF-36 questionnaires. All DRI-parameters were improved (p < 0,05) after three-years of follow-up compared to preoperative values. The functional tests in the ATFP showed an improvement (p < 0.05) in core muscle strength and stability, persisting back and abdominal muscle strength compared to preoperative values as well as an improvement compared to the one-year follow-up values (p < 0.05). UDI-6 and IIQ-7 results were improved (p < 0.05) compared to preoperative values and showed consistent values compared to the one-year follow-up. Quality of life measured with SF-36 were improved compared to preoperative values and showed consistent values compared to the one-year follow-up (p < 0.05). Conclusions The functional improvement of surgical reconstruction of the DRA persisted for three years in this series of post-partum women with DRA.

Long-term quality of life evaluation of patients with total hip arthroplasty

2003 ◽  
Vol 13 (3) ◽  
pp. 167-176 ◽  
Author(s):  
K. Knahr ◽  
R. Jagsch ◽  
I. Kryspin-Exner
Keyword(s):  
Quality Of Life ◽  
Total Hip Arthroplasty ◽  
Functional Capacity ◽  
Hip Arthroplasty ◽  
Harris Hip Score ◽  
Total Hip ◽  
One Year ◽  
The One

The aim of the study was to evaluate the clinical and psychological situation of total hip arthroplasty (THA) patients before and one year and five years after surgery. Data of 101 patients were available for the one-year and of 69 patients for the five-year follow-up. Quality of Life (QoL) data were collected using the Nottingham Health Profile (NHP), functional capacity comprised patient's self-assessment (Functional Outcome Questionnaire Hannover, FFbH) and surgeon's assessment (Harris Hip Score, HHS). While all dimensions of QoL and functional capacity except social isolation showed significant improvement at the one-year follow-up, only pain scores showed further improvement at the five-year evaluation. Implantation of THA is accompanied by significant increases in QoL and functional capacity. Stabilised scores were found at the five-year evaluation while significant increases could be observed after one year.

Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis

2003 ◽  
Vol 9 (3) ◽  
pp. 280-283 ◽  
Author(s):  
James D Bowen ◽  
Kenneth Maravilla ◽  
Solomon B Margolin
Keyword(s):  
Quality Of Life ◽  
Multiple Sclerosis ◽  
Rating Scale ◽  
Short Form ◽  
Primary Progressive ◽  
Secondary Progressive ◽  
The Mean ◽  
One Year ◽  
The One

Background: Pirfenidone is an oral medicatio n with a number of actions affecting the immune system. It has been proposed as a possible treatment for multiple sclerosis (MS). Methods: An early-phase study of progressive forms of MS was conducted. Pirfenidone was slowly titrated to 2400 mg/day. Safety, clinical, quality-of-life, and magnetic resonance image (MRI) outcomes were measured. Results: Twenty people were enrolled (13 with secondary progressive and seven with primary progressive MS). The mean age was 47.7 years; the mean Expanded Disability Status Scale (EDSS) was 5.15; 75% were female. Eighteen patients achieved the full dose, although five additional patients eventually had to decrease the dose, primarily because of nausea. The Neurologic Rating Scale showed a slight worsening, from 69.89-8.4 at baseline to 71.89-8.9 at one year (P=0.03). O ther clinical outcomes remained stable, including the EDSS, ambulation index, and nine-ho le peg test. The Short-Form Health Survey (SF-36) quality-of-life measure remained unchanged. C omparisons of MRI scans at baseline and one year found that 715 plaques were unchanged, six were better, and 10 were worse. Three patients had plaques that improved and two patients had plaques that were worse. There were eight gadolinium-enhancing lesions on the baseline scans and 14 on the one-year scans. Conclusions: Pirfenidone was well tolerated in patients with MS. Patients with primary progressive or secondary progressive MS tolerated the medicatio n and remained clinically stable during the one year of follow up. Placebo-controlled blinded studies are needed to determine clinical effectiveness.

Decade-long use of continuous combined hormone replacement therapy is associated with better health-related quality of life in postmenopausal women, as measured by the generic 15D instrument

2005 ◽  
Vol 11 (4) ◽  
pp. 145-151 ◽  
Author(s):  
Stiina Ylikangas ◽  
Harri Sintonen ◽  
Jorma Heikkinen
Keyword(s):  
Quality Of Life ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related ◽  
One Year ◽  
The One

Objective: To examine quality of life after a decade of continuous combined hormone replacement therapy. Study design: The 15D, a generic health-related quality-of-life (HRQoL) instrument, was used to evaluate trends in HRQoL in women who used continuous combined hormone replacement therapy (ccHRT; Indivina®, Orion Pharma, Finland) for up to nine years. These women had a mean age of 56 years of age at the start of therapy. Control data on HRQoL were obtained from age-matched women participating in Finnish population health surveys. Results: Relative to controls, ccHRT was associated with significantly better HRQoL after six and nine years of treatment. Dose minimization at 8.5 years was not associated with a decline in HRQoL in the ensuing six months. One year after discontinuation of ccHRT there was evidence of a decline in HRQoL in women who discontinued ccHRT as planned, whereas HRQoL was maintained in women who had continued or resumed ccHRT during the one-year post-study follow-up. The benefits of ccHRT were apparent in multiple dimensions of the 15D, being largest and most robustly reproduced in the dimension 'discomfort and symptoms'. It is conjectured that the effectiveness of ccHRT in relieving symptoms of menopause may have contributed to the improved HRQoL scores registered in other dimensions, in addition to any direct effects of ccHRT on specific aspects of those other dimensions. Conclusions: These data indicate that up to 10 years of low-dose ccHRT has sustained value in the enhancement of HRQoL when used by women for whom relief of symptoms of menopause and control of bleeding are primary objectives of treatment.

CURRENT ASPECTS OF DRUG THERAPY OF CHRONIC HEART FAILURE SYNDROME

2020 ◽  
Vol 4 (2) ◽  
pp. 1085-1096
Author(s):  
T.V. Statkevich ◽  
◽  
N.P. Mitkovskaya ◽  
◽  
Keyword(s):  
Quality Of Life ◽  
Heart Failure ◽  
Drug Therapy ◽  
Chronic Heart Failure ◽  
Clinical Symptoms ◽  
Nyha Class ◽  
Treatment And Prevention ◽  
One Year ◽  
The One

Chronic heart failure (CHF) is an important problem for the country, which has both medical and socio-economic aspects. The presence of the syndrome not only significantly increases the risks of an unfavorable course of diseases underlying its etiological basis, but in itself, through the development of decompensation, causes a high frequency of deaths. Despite all the advances in pharmacotherapy, the prognosis of heart failure remains poor. More than 40% of patients die within 4 years after the diagnosis of heart failure, and the one-year mortality rate for patients with severe CHF (NYHA class IV) exceeds 50%. The foregoing determines the need and importance of using all possible drug and non-drug therapy technologies aimed at reducing mortality, increasing the duration and quality of life of patients with CHF, as well as reducing the number and likelihood of decompensation and related hospitalizations, and makes this direction one of the priorities in medicine. The article describes current approaches to the treatment of patients with CHF syndrome from the perspective of evidence-based medicine and taking into account the recommendations of leading international organizations for the treatment and prevention of cardiovascular diseases. The drugs used were analyzed in terms of their influence on clinical symptoms, quality of life of patients, the risk of hospitalization due to decompensation of CHF, and mortality rates. The emphasis is made on the possibilities, mechanism of action and further prospects for the use of a new class of drugs in the treatment of CHF, acting at the level of the renin-angiotensin-aldosterone system and the system of neutral endopeptidases - inhibitors of angiotensin-neprilisin receptors.

scholarly journals Quality of life in children with atopic dermatitis: A one-year prospective cohort study

2021 ◽  
Vol 0 ◽  
pp. 1-5
Author(s):  
Tatjana Gazibara ◽  
Vesna Reljic ◽  
Slavenka Jankovic ◽  
Jelena Peric ◽  
Milos Nikolic ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Atopic Dermatitis ◽  
Life Quality ◽  
Severe Atopic Dermatitis ◽  
Related Quality ◽  
Quality Of Life Index ◽  
One Year ◽  
The One

Background: Literature on the quality of life trends across time in children with atopic dermatitis are scarce. Aims: To assess factors associated with quality of life of children with atopic dermatitis after a one-year follow-up and to examine the factors contributing to greater improvement in the atopic dermatitis-related quality of life over one year. Methods: Our cohort consisted of 98 children who were treated for atopic dermatitis at the clinic of dermatovenereology. Data collection included atopic dermatitis scoring using the SCORing Atopic Dermatitis (SCORAD) index, Children’s Dermatology Life Quality Index (CDLQI) for children aged > four years and Infants’ Dermatitis Quality of Life Index (IDLQI) for children aged 0–4 years. Categorization of the impairment of quality of life score due to atopic dermatitis was as follows: mild (score from 0 to 6), moderate (score from 7 to 12) and severe (score from 13 to 30). The cohort was followed for one year after which a total of 80 children were reassessed. Results: Improvements of both CDLQI and IDLQI were observed in children whose impairment of quality of life due to atopic dermatitis after one year was ‘mild’. This was not observed in children whose atopic dermatitis caused either ‘moderate’ or ‘severe impairment’ of their quality of life. Adjusted analysis showed that lower initial SCORAD and greater improvement in SCORAD after the one-year follow-up were associated with a better quality of life at follow-up. Limitations: The size of our cohort was relatively small. Study participants were recruited from the largest urban and medical referral center in Serbia. Persons from suburban or rural regions may have had different perceptions of atopic dermatitis-related quality of life. Conclusion: Children with less severe atopic dermatitis were more likely to improve their atopic dermatitis-related quality of life. Lower SCORAD was associated with both better quality of life initially and greater improvement in quality of life after one year of follow-up.

Sign in / Sign up

Export Citation Format

Share Document